Alpine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alpine

Quick Facts: Identity Snapshot

Property Description
Active ingredient Multivitamin, Multimineral, Co-dergocrine Mesylate
Form Tablet or Capsule (Oral preparation)
Pharmacological class Cerebral Metabolism Enhancer with Nutritional Supplement
General purpose Metabolic support and Neuroprotection
Origin Synthetic and Derived Biological Components

What Type of Medicine is Alpine? (Classification and Identity)

Alpine is defined as a specialized fixed-dose combination product, encompassing both a Multivitamin and Multimineral Supplement and a specific pharmacological agent. This makes it a complex poly-nutrient preparation. The primary distinguishing component is Co-dergocrine Mesylate, an Ergot alkaloid derivative, which places the medicine into the functional pharmacological class of Cerebral Metabolism Enhancers. This substance is clinically recognized for supporting metabolic activity in neurological contexts, a distinction that elevates Alpine beyond standard Nutritional deficiency management. Alpine is exclusively administered as an Oral preparation, typically available as a Tablet or Capsule.


What is Alpine's Unique Composition and Purpose?

The Alpine complex formulation integrates an extensive range of Active ingredients, including B group vitamins (Vitamin B6, Folic Acid), Vitamin D3, and Essential minerals such as Iron (Ferrous Fumarate) and Zinc (Zinc Sulphate). The formula also features potent Antioxidant supplement components like Lutein and Lycopene. This robust, multi-ingredient matrix is designed to provide synergistic action aimed at both providing comprehensive metabolic support and neuroprotection.

The general purpose is to deliver systemic health benefits. The Essential minerals and Vitamins address potential Nutritional deficiency and support fundamental Cellular energy production. The combination is used to support general vitality and cognitive function, with the Ergot alkaloid derivative acting as a general tonic.

Regulatory References

  1. Ergot Alkaloids - LiverTox - NIH

What side effects are possible with Alpine?

Official Adverse Reactions and Safety Constraints

This section outlines the officially documented adverse effects and safety characteristics for a combination product containing Co-dergocrine Mesylate (an Ergot alkaloid derivative) and a Multivitamin/Multimineral complex, based strictly on government regulatory documents.

Adverse Reactions by System Organ Class (SOC)

System Organ Class (SOC) Officially Listed Adverse Reactions
Gastrointestinal Disorders Nausea, Vomiting, Upset stomach, Diarrhea, Stomach cramps
Nervous System Disorders Dizziness, Drowsiness, Lightheadedness, Somnolence
Skin Disorders Skin rash, Flushing
Cardiac Disorders Slow heart rate, Hypotension, Hypertension

Nausea and vomiting are often described in regulatory summaries as common or frequently experienced effects associated with the active pharmacological component.


Serious Adverse Reactions and Risk Factors

The regulatory profile highlights rare but serious risks associated with the ergot alkaloid component:

  • Fibrotic Complications: The potential for pleural and retroperitoneal fibrosis has been documented with prolonged daily use of related ergot alkaloids.
  • Vascular Events: A risk of severe vasospasm (vessel constriction) exists, which may lead to cerebral or peripheral ischemia, particularly when co-administered with strong inhibitors of the CYP3A4 enzyme.

Population-Specific Safety Restrictions

Population Group Regulatory Constraint (Mandatory Safety Statements)
Pregnancy/Lactation Contraindicated/Not Recommended due to potential oxytocic activity.
Pediatric Patients Not Recommended as safety and effectiveness are not established.
Severe Hepatic Impairment Contraindicated. Use in any hepatic impairment requires extreme caution.

Use of this medicine requires caution and monitoring in older adults and patients with pre-existing renal impairment. Additionally, it must be avoided in individuals with a known allergy to ergot alkaloids or a history of ischemic heart disease or uncontrolled hypertension.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Alpine (Co-dergocrine Mesylate) outlines the specific manifestations and required emergency response in the event of an overdose. Immediate medical attention must be sought for any suspected overdose due to the potential for severe, life-threatening outcomes.


Documented Overdose Manifestations

Acute overdose of the pharmacological component may present with clinical signs such as tremulousness, spasticity, headache, and flushing of the face. Serious effects primarily involve the cardiovascular and central nervous systems. These include severe hypotension (low blood pressure), progressing to circulatory collapse, and ultimately coma. The presentation is officially associated with excessive consumption of the product.


Required Emergency Actions

Urgent professional care is mandated due to the severity risks. According to regulatory documents, treatment is strictly symptomatic and supportive, as no specific antidote is known. Supportive measures include procedures to empty the stomach, such as gastric lavage or emesis, maintaining an adequate airway, and administering Intravenous fluids. Careful supervision of the patient's fluid intake and output is required, and vasopressor agents may be utilized if circulatory collapse necessitates intervention. Official guidance notes that forced diuresis is ineffective for drug elimination.

Therapeutic Uses of Alpine

What Alpine Treats: Main Uses and Benefits


Alpine is commonly used to provide symptomatic support across therapeutic domains involving age-related cognitive decline and associated functional deficits. In the therapeutic domain where Co-dergocrine Mesylate (Dihydroergotoxine Mesylate) is applied, it is generally used for managing the mild to moderate stages of age-related cognitive impairment and specific forms of dementia, including those associated with Alzheimer's and Parkinson's disease. The medication may be relevant for easing symptoms such as difficulty with memory, poor attention, and general confusion. This combination supports patients whose cognitive decline leads to symptoms that interfere with daily functioning, such as struggling with self-care activities.

Quick Fact: Relief for Cognitive Impairment Focus Symptom Category Benefit
Primary Memory, Attention, Concentration May support mental functioning and alertness
Secondary Confusion, Emotional Lability May assist with maintaining functional stability
Adjuvant Nutrient Deficit Symptoms Contributes to general well-being during symptomatic phases

The nutritional components are relevant for supporting key biological processes, including cellular energy production, and the medicine is also applied as an adjunctive measure in contexts involving heightened systemic burden or neurological recovery. “It provides support that helps ease the overall symptom burden,” assisting patients with maintaining functional stability during symptomatic phases.


Eligibility and Restrictions for Use

Alpine is officially approved for use in adults who are experiencing signs of age-related cognitive impairment and associated dementias. Regulatory labeling strictly defines eligibility, outlining specific populations who must not use the medicine, as well as groups requiring limited or conditional use.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated for any individual with a known hypersensitivity to Co-dergocrine Mesylate or other ingredients. It must not be used by patients diagnosed with acute or chronic psychosis. Additionally, official prescribing information prohibits concurrent use with strong CYP3A4 inhibitors (like certain antifungal agents) and specific triptans used for migraine.

Restricted and Conditional Use

Use is not recommended for children under 18 years of age because the safety and effectiveness in this pediatric population are not clinically established.

Use in older adults and patients with severe hepatic impairment or renal impairment requires extreme caution and close clinical monitoring, often necessitating dose adjustments. The medicine is also not recommended for use in women who are pregnant or breastfeeding, unless a physician determines it is absolutely essential.

What should I know about interactions with other medicines?

Alpine Interactions with other medicines and products

Alpine has the potential to interact with a variety of prescription medicines, over-the-counter drugs, and herbal supplements. These interactions can alter how Alpine is processed by the body (its pharmacokinetics), potentially changing its effectiveness or increasing the risk of side effects.

Drug-Drug Interactions

Alpine is metabolized by certain liver enzymes, primarily Cytochrome P450 (CYP) 3A4 and to a lesser extent, CYP2D6. Concurrent use of medicines that inhibit these enzymes can increase the concentration of Alpine in the blood, raising the risk of adverse reactions. Conversely, medicines that induce (speed up) these enzymes may decrease Alpine levels, potentially reducing its therapeutic effect. Examples of medicines that can inhibit or induce these enzymes include certain antifungals, antibiotics, and medications used to treat HIV/AIDS or seizure disorders.

Interaction Type Potential Effect
CYP3A4 Inhibitors Increased Alpine blood concentration, increased side effects.
CYP3A4 Inducers Decreased Alpine blood concentration, reduced effectiveness.
CNS Depressants Increased sedation and drowsiness.

Other Interactions

  • Alcohol: Consuming alcohol while taking Alpine can increase the depressant effects on the central nervous system, leading to enhanced drowsiness, dizziness, and impaired coordination. Patients should avoid alcohol use.
  • Grapefruit Juice: Grapefruit juice is a known inhibitor of the CYP3A4 enzyme and can increase Alpine's blood concentration, similar to drug interactions involving CYP3A4 inhibitors. Avoid consuming grapefruit or grapefruit juice while on this medication.
  • Herbal Products: Supplements such as St. John's Wort can act as enzyme inducers, potentially lowering Alpine's concentration and effectiveness. Discuss all supplements with a healthcare provider.

Mechanism of Action

The mechanism of Alpine is a dual, synergistic action focused on modulating central nervous system signaling pathways and supporting cellular energy metabolism.

Receptor Modulation and Influenced Cerebral Perfusion

The pharmacological component, Co-dergocrine Mesylate, acts as a mixed partial agonist and antagonist across key alpha-adrenergic, dopaminergic, and serotonergic receptors. This pleiotropic modulation alters central vasomotor signals, influencing vascular tone. This mechanism influences signals that regulate vascular resistance, which is associated with increased cerebral blood flow (CBF) and oxygen supply to neuronal tissues.

Direct Neuronal Metabolic Stimulation

The drug directly stimulates the neuronal uptake and utilization of glucose (CMRGlc) in specific brain regions. This action is synergistically supported by the included B-vitamins and minerals, which function as essential enzymatic co-factors necessary for the synthesis of neurotransmitters and the efficient generation of cellular energy (ATP) in the mitochondria. The combined effect modulates the metabolic process, promoting efficient substrate utilization and influencing the neuronal bioenergetic state.

Co-factor Function and Redox Stabilization

The nutritional components, including specific antioxidants, engage in free radical scavenging and support the necessary biochemical integrity of the nerve cell. This mechanism influences the redox balance and modulates cellular processes associated with oxidative stress, thereby complementing the direct metabolic enhancement and contributing to the overall physiological activity.

Dosage and Administration Information

Alpine is administered solely through the oral route, typically supplied as a tablet or capsule. The prescribed use is structured as a long-term, continuous course dictated by the amount of the pharmacological component, Co-dergocrine Mesylate, taken per day. Dosing regimens for the adult population are standardized based on the concentration of the oral preparation. The standard approved regimen is typically 1 mg of the active component taken three times per day (TID). An alternative regimen may involve taking a single unit dose of 4.5 mg once daily (QD), depending on the specific product formulation.

The oral preparations of Alpine must be swallowed whole with water and should not be crushed, broken, or chewed. This instruction ensures the correct rate of drug delivery. The medicine offers flexibility in administration timing, as it can generally be taken with or without food, although administration is sometimes preferred before meals.

Due to the nature of the usage protocol, the commencement of observable symptomatic relief is typically gradual, requiring 3 to 4 weeks of continuous administration before initial changes may be noted. A full therapeutic course of treatment is structured to last for 3 to 6 months before a formal assessment of continued use is typically made. For special populations, such as those with renal impairment, it is noted that no specific dosage adjustment is required.

Recent Clinical Evidence

Evidence for Symptomatic Support in Age-Related Cognitive Impairment

Research for the Co-dergocrine Mesylate component involves older Randomized Controlled Trials (RCTs) and systematic Meta-analyses focused on older adults with age-related cognitive decline or mild to moderate dementia. Studies monitored functional stability and symptoms like difficulty with memory. Findings describe patterns observed where some trials reported measurements of difference in neuropsychological test scores. Findings were mixed, and comparative research with other available options is limited. Long-term effects are not fully established.

Research on Nutritional and Metabolic Support

The multivitamin/multimineral component was studied in large-scale, long-term RCTs and systematic Reviews involving healthy older adults. Research examined whether continuous supplementation may be linked to a change in cognitive outcomes. Recent long-term studies (two to three years) have reported patterns related to measured change in immediate memory compared to placebo. Evidence is limited by inconsistent findings from earlier trials. Data are still emerging regarding whether cognitive changes translate into noticeable daily functional outcomes.

Long-Term Research and Follow-up Durations

Controlled trials for the Co-dergocrine Mesylate component typically observed responses over intermediate-term intervals (3 to 6 months). The key nutritional trials spanned two or three years of continuous use. However, long-term effects are not fully established for the combination product, and data for extended outcomes beyond the duration of the major studies remain insufficient.

Evidence in Specific Patient Groups

The research was primarily evaluated in the elderly population with age-related cognitive impairment. Clinical evaluation of the Co-dergocrine Mesylate component has not been performed in patients below 18 years of age. Research exploring the effects of the combination in younger adults or those with acute health conditions is limited, meaning results apply only to the older adult populations studied.

Key Research Limitations and Uncertainties

Evidence quality varies across studies. For the Co-dergocrine Mesylate component, a key limitation is the lack of comparative research. For the nutritional components, certainty remains low regarding the consistency of results across all cognitive domains. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain—about the full impact of the multi-ingredient combination.

Key Studies & References NIH: Ergot Alkaloids and Vascular Function (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Alpine (FAQ)


Q: What is Alpine actually used for, besides the main condition?

Official product information defines the primary uses of Alpine. In addition to age-related cognitive impairment, the drug's active component is also listed for use in managing dementia associated with Parkinson's disease. Furthermore, regulatory documents state it can be used for the preventive treatment of certain vascular headaches.


Q: Does Alpine treat the underlying cause or just the symptoms?

The mechanism of Alpine involves modifying cerebral metabolism and signaling pathways in the brain. This action supports underlying biological processes associated with impaired function. Separately, the medication is also officially indicated to improve noticeable effects, such as difficulties with concentration.


Q: Is it normal to feel slightly dizzy after starting Alpine?

Dizziness and lightheadedness are listed among the known, documented adverse effects of Alpine. It is recommended to observe and monitor any effects you experience. Serious side effects, though rare, should be communicated promptly to a healthcare provider.


Q: Can Alpine be taken at the same time as my daily vitamin supplements?

Regulatory information indicates that Alpine may interact with other medicines, including over-the-counter vitamins and nutritional supplements. Therefore, providing a complete list of all supplements to your healthcare provider is important for a full safety review.


Q: Can individuals over 65 years old safely use Alpine?

Clinical research for Alpine was primarily conducted in the elderly population, indicating that it can be used by individuals over 65. However, regulatory warnings stress that it must be used with extreme caution in this age group. This is due to a potentially increased risk of experiencing severe adverse effects compared to younger patients.


Q: Why does the packaging for Alpine sometimes include a specific warning label?

Medicines belonging to the same pharmacological class as the active component in Alpine may be required to carry a Boxed Warning on their packaging. This is a special type of label mandated by regulatory bodies to draw attention to serious or potentially life-threatening risks. It functions to alert both patients and healthcare providers to key safety information.


Q: Is it true that Alpine is less effective for certain populations?

Official prescribing information states that Alpine is not recommended for pediatric patients under the age of 18. This is because the safety profile and whether the medicine is effective for this specific age group have not been clinically established in research studies.


Q: Are there different forms of Alpine (tablet, liquid, extended-release)?

Regulatory information describes Alpine as an oral preparation, most often available as a tablet or capsule. These forms are designed for patient use outside of a clinical setting. Separately, a specialized injectable form of the active component may be available for use only within hospital or clinical settings.


Q: Does my diet need to change when I start taking Alpine?

Alpine can generally be taken with or without food, offering flexibility in administration timing. However, official guidance specifically advises the avoidance of grapefruit juice and products containing it. This is because grapefruit juice is known to interact with the liver enzymes that metabolize the drug.


Q: What is the typical monitoring process a doctor uses while a patient is on Alpine?

For patients with pre-existing kidney or liver impairment, close monitoring of these organ functions is typically required throughout treatment. Additionally, official regulatory documents note that blood pressure and blood sugar levels may also be monitored regularly as part of the overall assessment of the patient's physiological status.


Q: What is the difference between a side effect and an allergic reaction to Alpine?

A side effect is a common or expected response to the medicine, such as nausea or dizziness, that is documented in official safety summaries. An allergic reaction (or hypersensitivity) is a serious, rare immune response to the drug's components. A known allergy to the active component is listed in regulatory documents as a major contraindication, which means the drug is generally excluded from use.


Q: What is the likelihood of experiencing a severe interaction with Alpine?

Official safety documents emphasize that Alpine is known to interact with a wide range of other medicines, which has the potential to cause severe adverse effects. Regulatory guidance stresses the importance of having all current prescription medications, over-the-counter products, and supplements reviewed by a healthcare provider.


Q: How long do any temporary side effects from Alpine typically last?

Official regulatory summaries note that certain temporary side effects, such as minor gastric upsets, may occur early in treatment. These types of effects usually disappear on their own as the body adjusts to the medication and typically do not typically require specific medical measures.


Q: Are there any common over-the-counter pain relievers that interact with Alpine?

Official warnings broadly state that Alpine may interact with many other prescription and non-prescription medicines, including over-the-counter (OTC) drugs and cold/flu medications. Because the drug is metabolized by certain liver enzymes that can be affected by OTCs, regulatory guidance emphasizes the importance of informing a healthcare provider of all medicines currently being taken.


Q: Can Alpine affect your mood or energy levels?

The active component in Alpine is known to affect the central nervous system, and side effects such as drowsiness or somnolence are listed. Furthermore, official information notes that if the medication is stopped, symptoms like increased irritability or depression have been reported.


Q: What is the recommended approach if a dose of Alpine is missed?

Official regulatory guidance for medications generally states that a patient should never take a double dose to compensate for a missed one. Specific instructions for handling a missed dose, including whether to take the dose or simply skip it, are generally provided by the healthcare professional.


Q: What are the official restrictions for driving or operating machinery while on Alpine?

Official safety documents advise caution regarding activities that require full mental alertness. Regulatory information indicates that due to the potential for adverse effects like dizziness or drowsiness, driving or operating heavy machinery is restricted if these central nervous system effects are experienced.


Q: Why do some people experience sleeping issues when taking Alpine?

While Alpine is commonly associated with drowsiness, some official safety data has noted that insomnia (difficulty sleeping) has been reported. This symptom is sometimes specifically noted in connection with the discontinuation of the active component of the drug.


Q: What information should I know about stopping Alpine treatment?

Regulatory guidance emphasizes that discontinuation of the medicine before completing the prescribed course or without physician consultation is not recommended. For some individuals, stopping the medicine may require a process of dose tapering (gradually reducing the amount taken) to manage potential effects.


Q: What happens if I accidentally take more Alpine than prescribed?

Official regulatory documents treat all instances of accidentally taking more medicine than prescribed as a serious matter requiring reporting. Any symptoms or adverse events associated with taking an excessive amount of Alpine should be promptly communicated to a healthcare provider.


Q: Can Alpine cause headaches or migraines?

According to official product labeling, the active component in Alpine is indicated for the treatment or prevention of certain types of headaches, specifically vascular headaches (prophylactic use). Headaches themselves are generally not listed as a common adverse reaction, but rather a symptom the drug may be used to address.

How should Alpine be stored and disposed of?

Storage Requirements

Alpine must be stored within the room temperature range, typically 20 C to 25 C left(68 F to 77 F ight). The medicine requires protection from light and must be kept away from excessive heat and moisture; therefore, it should not be stored in humid areas like the bathroom. To maintain stability, the product must remain in its original container, which must be kept tightly closed.

Child-Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children.

Official disposal instructions prioritize the use of a drug take-back program for unused or expired product. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance and placed in a sealed container for household trash disposal. Do not flush Alpine down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alpine found in:

A-Z Index: